Rosmarinic acid and ursolic acid alleviate deficits in cognition, synaptic regulation and adult hippocampal neurogenesis in an Aβ 1-42 -induced mouse model of Alzheimer's disease.
Level 5 - mechanism / opinion, no new human data
Animal research (preclinical mouse model)
PubMed 33601255 · doi:10.1016/j.phymed.2021.153490
What was done
BALB/c mice received stereotaxic hippocampal injections of either Aβ 1-42 or control injections to model Alzheimer's disease pathology. Across ten experimental groups, mice received oral administration of vehicle, an ethanolic extract of Rosmarinus officinalis, ursolic acid, rosmarinic acid, or donepezil. Behavior was assessed using the Morris water maze, novel object recognition test, and elevated plus maze. Hippocampal tissue was evaluated post-mortem via immunohistochemistry and gene expression analysis for neurogenic markers (Ki67, NeuN, DCX) and synaptic markers (Syn I, II, III, Synaptophysin, PSD-95).
What was found
No numerical values, effect sizes, or statistical metrics are reported in the abstract. Qualitatively, treatment with rosmarinic acid or ursolic acid reversed Aβ 1-42-induced deficits in spatial memory, recognition memory, and anxiety-like behavior. Treatment also normalized neuronal density and the expression levels of the evaluated neurogenic and synaptic markers.
Why it matters
This study provides preclinical evidence that specific active constituents of rosemary can counteract acute amyloid-beta-induced neurotoxicity by supporting hippocampal neurogenesis and synaptic regulation.
Limits
The study was conducted in a rodent model of acute Aβ 1-42 injection, which does not fully capture chronic human Alzheimer's disease pathology. The abstract omits total sample size, compound dosages, treatment duration, and all quantitative data.
Cited by
- partial Ursolic acid improves cerebral blood flow and improves cognition.